These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18605070)

  • 1. Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.
    Sousa CS; Fonseca T; Clara JG
    Rev Port Cardiol; 2008 Apr; 27(4):513-27. PubMed ID: 18605070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
    Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
    Zuern CS; Lindemann S; Gawaz M
    Semin Thromb Hemost; 2009 Apr; 35(3):295-306. PubMed ID: 19452405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus.
    Bulatova NR; Yousef AM; AbuRuz SM
    Thromb Res; 2007; 121(1):43-50. PubMed ID: 17462716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin: promise and resistance in the new millennium.
    Patrono C; Rocca B
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):s25-32. PubMed ID: 18174450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who needs antiplatelet therapy?
    Moher M; Lancaster T
    Br J Gen Pract; 1996 Jun; 46(407):367-70. PubMed ID: 8983259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet inhibitors: what are the data in women?
    Tempelhof MW; Newby LK
    Cardiol Rev; 2008; 16(1):23-9. PubMed ID: 18091399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
    Klomp CM; ten Cate H; Stehouwer CD; Schaper NC
    Ned Tijdschr Geneeskd; 2009; 153():A109. PubMed ID: 19785798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
    Hennekens CH; Sechenova O; Hollar D; Serebruany VL
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acetylsalicylic acid does not prevent cardiovascular disease. Poor scientific support for therapeutic guidelines according to primary prevention studies].
    Mooe T
    Lakartidningen; 2006 Sep 20-26; 103(38):2732-6. PubMed ID: 17058766
    [No Abstract]   [Full Text] [Related]  

  • 16. [Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
    Legrand DA; Scheen AJ
    Rev Med Suisse; 2006 Aug; 2(76):1904-8. PubMed ID: 16972540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender and stroke: acute phase treatment and prevention.
    Sacco S; Cerone D; Carolei A
    Funct Neurol; 2009; 24(1):45-52. PubMed ID: 19403054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.